The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ciprostene     (5Z)-5-[5-hydroxy-4-[(E)-3- hydroxyoct-1...

Synonyms: Ciprosteno, Ciprostenum, AC1O5S0J, 81845-44-5, UNII-KZ075BHY4P, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ciprostene

  • Ten patients with peripheral vascular disease and claudication received ciprostene (titrated to 120 ng/kg/min) infused over 8 hours 1 day per week for 4 consecutive weeks [1].
  • In patient #5 with a history of arrhythmias, the last ciprostene infusion had to be discontinued at 4.5 hours due to arrhythmias but his data were included into the evaluation [2].
  • When patients were characterized according to their clinical status, these differences were accounted for by patients with unstable angina receiving ciprostene [3].
  • In contrast, coronary artery stenoses in patients receiving ciprostene (n = 12) measured 83 +/- 3% before PTCA, 31 +/- 4% after PTCA and 55 +/- 9% at 6 month, being still significantly different from pre-PTCA value (P less than 0.05) [3].

High impact information on Ciprostene


Biological context of Ciprostene


Analytical, diagnostic and therapeutic context of Ciprostene


  1. Continuous intravenous dosing with ciprostene using a portable pump in ambulatory patients. Wolf, D.L., Metzler, C.M., Froeschke, M.O., Luderer, J.R. Journal of clinical pharmacology. (1993) [Pubmed]
  2. Ciprostene in patients with peripheral vascular disease (PVD). An open-label, tolerance trial. Linet, O.I., Luderer, J.R., Froeschke, M., Welch, S., Metzler, C.M., Eckert, S.M. Prostaglandins Leukot. Essent. Fatty Acids (1988) [Pubmed]
  3. Effects of ciprostene on restenosis rate during therapeutic transluminal coronary angioplasty. Darius, H., Nixdorff, U., Zander, J., Rupprecht, H.J., Erbel, R., Meyer, J. Agents Actions Suppl. (1992) [Pubmed]
  4. Prostacyclin analogs inhibit fibroblast migration. Kohyama, T., Liu, X., Kim, H.J., Kobayashi, T., Ertl, R.F., Wen, F.Q., Takizawa, H., Rennard, S.I. Am. J. Physiol. Lung Cell Mol. Physiol. (2002) [Pubmed]
  5. Tolerance and pharmacology of ciprostene, a stable epoprostenol (prostacyclin) analogue in humans. Linet, O.I., Nishizawa, E.E., Schaub, R.G., VanderLugt, J.T., Greenwald, C.A. Journal of clinical pharmacology. (1986) [Pubmed]
  6. High-performance liquid chromatography method for the separation of isomers of 9 beta-methylcarbacyclin (ciprostene) and the analysis of pharmaceutical samples. Theis, D.L., Rusk, M.L., Plaisted, S.M., Snider, B.G. J. Chromatogr. (1985) [Pubmed]
  7. Ciprostene, a stable prostacyclin analog, produces peripheral vasodilation, platelet inhibition and increased clot dissolution in the cat. Schaub, R.G. Prostaglandins (1988) [Pubmed]
WikiGenes - Universities